Literature DB >> 19728047

Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.

Jeffrey D Kearbey1, Wenqing Gao, Scott J Fisher, Di Wu, Duane D Miller, James T Dalton.   

Abstract

PURPOSE: Although androgens are known to protect bone, side effects and poor oral bioavailability have limited their use. We previously reported that S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (S-4) is a potent and tissue-selective androgen receptor modulator (SARM). This study was designed to evaluate the skeletal effects of S-4 in an osteopenic model.
METHODS: Aged female rats were gonadectomized or sham operated on day 1 and assigned to treatment groups. Dosing was initiated on day 90 and continued daily until day 210. Whole animal bone mineral density (BMD), body weight, and fat mass were determined by dual energy x-ray absorptiometry (DEXA). Regional analysis of excised bones was performed using DEXA or computed tomography. Femur strength was evaluated by 3-point bending.
RESULTS: S-4 restored whole body and lumbar vertebrae (L5-L6) BMD to the level of intact controls. Significant increases in cortical bone quality were observed at the femoral midshaft, resulting in increased load bearing capacity.
CONCLUSIONS: S-4 demonstrated partial/complete recovery of bone parameters to age-matched intact levels. Increased efficacy observed in cortical bone sites is consistent with reported androgen action in bone. The ability of S-4 to promote bone anabolism, prevent bone resorption, and increase skeletal muscle mass/strength positions these drugs as promising new alternatives for the treatment of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728047     DOI: 10.1007/s11095-009-9962-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

Review 1.  Androgens and osteoporosis.

Authors:  D Vanderschueren; L Vandenput
Journal:  Andrologia       Date:  2000-05       Impact factor: 2.775

2.  Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats.

Authors:  E Samnegård; M P Akhter; R R Recker
Journal:  Bone       Date:  2001-04       Impact factor: 4.398

Review 3.  New anabolic therapies in osteoporosis.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Endocrinol Metab Clin North Am       Date:  2003-03       Impact factor: 4.741

4.  Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.

Authors:  Donghua Yin; Yali He; Minoli A Perera; Seoung Soo Hong; Craig Marhefka; Nina Stourman; Leonid Kirkovsky; Duane D Miller; James T Dalton
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

5.  Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.

Authors:  Jeffrey D Kearbey; Wenqing Gao; Ramesh Narayanan; Scott J Fisher; Di Wu; Duane D Miller; James T Dalton
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.200

6.  Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat.

Authors:  C K Lea; A M Flanagan
Journal:  Am J Physiol       Date:  1998-02

7.  Pharmacodynamics of selective androgen receptor modulators.

Authors:  Donghua Yin; Wenqing Gao; Jeffrey D Kearbey; Huiping Xu; Kiwon Chung; Yali He; Craig A Marhefka; Karen A Veverka; Duane D Miller; James T Dalton
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

8.  Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.

Authors:  J D Kearbey; D Wu; W Gao; D D Miller; J T Dalton
Journal:  Xenobiotica       Date:  2004-03       Impact factor: 1.908

9.  Temporal relationship between bone loss and increased bone turnover in ovariectomized rats.

Authors:  T J Wronski; M Cintrón; L M Dann
Journal:  Calcif Tissue Int       Date:  1988-09       Impact factor: 4.333

10.  Muscle strength and fall rates among residents of Japanese and American nursing homes: an International Cross-Cultural Study.

Authors:  L A Lipsitz; I Nakajima; M Gagnon; T Hirayama; C M Connelly; H Izumo; T Hirayama
Journal:  J Am Geriatr Soc       Date:  1994-09       Impact factor: 5.562

View more
  8 in total

1.  Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.

Authors:  Minyoung Lim; Maya Otto-Duessel; Miaoling He; Leila Su; Dan Nguyen; Emily Chin; Tamara Alliston; Jeremy O Jones
Journal:  ACS Chem Biol       Date:  2014-01-03       Impact factor: 5.100

2.  Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis.

Authors:  D B Hoffmann; M Komrakova; S Pflug; M von Oertzen; D Saul; L Weiser; T A Walde; M Wassmann; A F Schilling; W Lehmann; S Sehmisch
Journal:  J Bone Miner Metab       Date:  2018-05-21       Impact factor: 2.626

3.  Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.

Authors:  Suriyan Ponnusamy; Ryan D Sullivan; Dahui You; Nadeem Zafar; Chuan He Yang; Thirumagal Thiyagarajan; Daniel L Johnson; Maron L Barrett; Nikki J Koehler; Mayra Star; Erin J Stephenson; Dave Bridges; Stephania A Cormier; Lawrence M Pfeffer; Ramesh Narayanan
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

Review 4.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 5.  Selective androgen receptor modulators for the treatment of late onset male hypogonadism.

Authors:  Christopher C Coss; Amanda Jones; Michael L Hancock; Mitchell S Steiner; James T Dalton
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

6.  Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model.

Authors:  Hannu T Aro; Julia Kulkova; Niko Moritz; Esa Kähkönen; Riina H Mattila
Journal:  Acta Orthop       Date:  2015-07-22       Impact factor: 3.717

7.  Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.

Authors:  Suriyan Ponnusamy; Sarah Asemota; Lee S Schwartzberg; Fouzia Guestini; Keely M McNamara; Mariaelena Pierobon; Alba Font-Tello; Xintao Qiu; Yingtian Xie; Prakash K Rao; Thirumagal Thiyagarajan; Brandy Grimes; Daniel L Johnson; Martin D Fleming; Frances E Pritchard; Michael P Berry; Roy Oswaks; Richard E Fine; Myles Brown; Hironobu Sasano; Emanuel F Petricoin; Henry W Long; Ramesh Narayanan
Journal:  iScience       Date:  2019-10-23

8.  Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.

Authors:  Ramesh Narayanan; Sunjoo Ahn; Misty D Cheney; Muralimohan Yepuru; Duane D Miller; Mitchell S Steiner; James T Dalton
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.